Trends in Opioid Medication Adherence During the COVID-19 Pandemic: Retrospective Cohort Study

Overview

Journal JMIR Public Health Surveill

Publisher JMIR Publications

Date 2023 Sep 1

PMID 37656492

Authors

Amir Marashi

David Warren

Gary Call

Mark Dras

Affiliations

Soon will be listed here.

Abstract

Background: The recent pandemic had the potential to worsen the opioid crisis through multiple effects on patients' lives, such as the disruption of care. In particular, good levels of adherence with respect to medication for opioid use disorder (MOUD), recognized as being important for positive outcomes, may be disrupted.

Objective: This study aimed to investigate whether patients on MOUD experienced a drop in medication adherence during the recent COVID-19 pandemic.

Methods: This retrospective cohort study used Medicaid claims data from 6 US states from 2018 until the start of 2021. We compared medication adherence for people on MOUD before and after the beginning of the COVID-19 pandemic in March 2020. Our main measure was the proportion of days covered (PDC), a score that measures patients' adherence to their MOUD. We carried out a breakpoint analysis on PDC, followed by a patient-level beta regression analysis with PDC as the dependent variable while controlling for a set of covariates.

Results: A total of 79,991 PDC scores were calculated for 37,604 patients (age: mean 37.6, SD 9.8 years; sex: n=17,825, 47.4% female) between 2018 and 2021. The coefficient for the effect of COVID-19 on PDC score was -0.076 and was statistically significant (odds ratio 0.925, 95% CI 0.90-0.94).

Conclusions: The COVID-19 pandemic was negatively associated with patients' adherence to their medication, which had declined since the beginning of the pandemic.

References

Khoury D, Preiss A, Geiger P, Anwar M, Conway K . Increases in Naloxone Administrations by Emergency Medical Services Providers During the COVID-19 Pandemic: Retrospective Time Series Study. JMIR Public Health Surveill. 2021; 7(5):e29298. PMC: 8163496. DOI: 10.2196/29298. View

Slat S, Thomas J, Lagisetty P . Coronavirus Disease 2019 and Opioid Use-A Pandemic Within an Epidemic. JAMA Health Forum. 2022; 1(5):e200628. DOI: 10.1001/jamahealthforum.2020.0628. View

Agh T, van Boven J, Wettermark B, Menditto E, Pinnock H, Tsiligianni I . A Cross-Sectional Survey on Medication Management Practices for Noncommunicable Diseases in Europe During the Second Wave of the COVID-19 Pandemic. Front Pharmacol. 2021; 12:685696. PMC: 8216671. DOI: 10.3389/fphar.2021.685696. View

Clement J, Jacobi M, Greenwood B . Patient access to chronic medications during the Covid-19 pandemic: Evidence from a comprehensive dataset of US insurance claims. PLoS One. 2021; 16(4):e0249453. PMC: 8016279. DOI: 10.1371/journal.pone.0249453. View

Kretchy I, Asiedu-Danso M, Kretchy J . Medication management and adherence during the COVID-19 pandemic: Perspectives and experiences from low-and middle-income countries. Res Social Adm Pharm. 2020; 17(1):2023-2026. PMC: 7158799. DOI: 10.1016/j.sapharm.2020.04.007. View

Currie J, Schnell M, Schwandt H, Zhang J . Trends in Drug Overdose Mortality in Ohio During the First 7 Months of the COVID-19 Pandemic. JAMA Netw Open. 2021; 4(4):e217112. PMC: 8047728. DOI: 10.1001/jamanetworkopen.2021.7112. View

Gomes T, Kitchen S, Murray R . Measuring the Burden of Opioid-Related Mortality in Ontario, Canada, During the COVID-19 Pandemic. JAMA Netw Open. 2021; 4(5):e2112865. PMC: 8155822. DOI: 10.1001/jamanetworkopen.2021.12865. View

Currie J, Schnell M, Schwandt H, Zhang J . Prescribing of Opioid Analgesics and Buprenorphine for Opioid Use Disorder During the COVID-19 Pandemic. JAMA Netw Open. 2021; 4(4):e216147. PMC: 8050741. DOI: 10.1001/jamanetworkopen.2021.6147. View

Warren D, Marashi A, Siddiqui A, Eijaz A, Pradhan P, Lim D . Using machine learning to study the effect of medication adherence in Opioid Use Disorder. PLoS One. 2022; 17(12):e0278988. PMC: 9754174. DOI: 10.1371/journal.pone.0278988. View

10.

Ma J, Bao Y, Wang R, Su M, Liu M, Li J . Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. Mol Psychiatry. 2018; 24(12):1868-1883. DOI: 10.1038/s41380-018-0094-5. View

11.

Hailu R, Mehrotra A, Huskamp H, Busch A, Barnett M . Telemedicine Use and Quality of Opioid Use Disorder Treatment in the US During the COVID-19 Pandemic. JAMA Netw Open. 2023; 6(1):e2252381. PMC: 10038015. DOI: 10.1001/jamanetworkopen.2022.52381. View

12.

Garfield S, Wheeler C, Boucher C, Etkind M, Lloyd J, Norton J . Medicines management at home during the COVID-19 pandemic: a qualitative study exploring the UK patient/carer perspective. Int J Pharm Pract. 2021; 29(5):458-464. PMC: 8436399. DOI: 10.1093/ijpp/riab050. View

13.

Elixhauser A, Steiner C, Harris D, Coffey R . Comorbidity measures for use with administrative data. Med Care. 1998; 36(1):8-27. DOI: 10.1097/00005650-199801000-00004. View

14.

Lintzeris N, Deacon R, Hayes V, Cowan T, Mills L, Parvaresh L . Opioid agonist treatment and patient outcomes during the COVID-19 pandemic in south east Sydney, Australia. Drug Alcohol Rev. 2021; 41(5):1009-1019. PMC: 8652992. DOI: 10.1111/dar.13382. View

15.

Mason M, Arukumar P, Feinglass J . The Pandemic Stay-at-Home Order and Opioid-Involved Overdose Fatalities. JAMA. 2021; 325(24):2495-2496. DOI: 10.1001/jama.2021.6700. View